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Abstract
Muramyl dipeptide is the minimal structure of peptidoglycan with adjuvant properties. Replacement of the N-acetylmuramyl
moiety and increase of lipophilicity are important approaches in the preparation of muramyl dipeptide analogues with improved
pharmacological properties. Mannose receptors present on immunocompetent cells are pattern-recognition receptors and by
mannose ligands binding they affect the immune system. Here we present the design, synthesis and biological evaluation of novel
mannosylated desmuramyl peptide derivatives. Mannose was coupled to dipeptides containing a lipophilic adamantane on N- or
C-terminus through a glycolyl or hydroxyisobutyryl linker. Adjuvant activities of synthesized compounds were investigated in the
mouse model using ovalbumin as an antigen. Their activities were compared to the previously described mannosylated adaman-
tane-containing desmuramyl peptide and peptidoglycan monomer. Tested compounds exhibited adjuvant activity and the strongest
enhancement of IgG production was stimulated by compound 21 (Man-OCH2-ᴅ-(1-Ad)Gly-ʟ-Ala-ᴅ-isoGln).
Introduction
Dendritic cells capture and internalize invading pathogens.
Pathogen-associated molecular patterns have been known for a
long time to affect the immune system of mammalian hosts and
therefore have been extensively studied as possible adjuvants
for vaccines. Peptidoglycan is a polymeric component of the
Gram-positive and Gram-negative bacterial cell wall. Break-
down products of polymeric peptidoglycan are called muropep-
tides. Muropeptides act as agonists of pathogen recognition re-
ceptors (PRRs) and therefore stimulate immune response and
induce T cell differentiation [1-3]. They activate innate immune
responses and contribute to the development of adaptive immu-
nity. Immune response is initiated by the activation of PRRs lo-
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Figure 1: Peptidoglycan fragments with immunostimulating properties.
cated on the immune cell surface, by cytosolic or endosomal
PRRs. PRRs are classified into: Toll-like receptors (TLRs),
RIG-I-like receptors (RLRs), NOD-like receptors (NLRs) and
C-type lectin receptors (CLRs) [4]. Muramyl dipeptide (MDP,
N-acetylmuramyl-ʟ-alanyl-ᴅ-isoglutamine) is the smallest pepti-
doglycan fragment (Figure 1) capable of replacing the whole
Mycobacterium in complete Freund’s adjuvant. MDP triggers
an immune response by activating the mammalian NOD-like re-
ceptor, nucleotide binding oligomerization domain-containing
protein 2 (NOD2). NOD2 is an intracellular protein that signals
via the NF-κB pathway to proximally activate innate immunity
through macrophage response as well as to more distally affect
adaptive immunity through the production of antigen-specific T
cells [5]. MDP binding to NOD2 has been confirmed [6]
as well as the crystal structure of NOD2 in the inactive ADP-
bound state [7]. MDP is the structural fragment of the peptido-
glycan monomer (PGM, Figure 1) which is used in this work.
PGM is a well-defined and characterized disaccharide
pentapeptide, β-ᴅ-GlcNAc-(1→4)-ᴅ-MurNAc-ʟ-Ala-ᴅ-isoGln-
mesoDAP(εNH2)-ᴅ-Ala-ᴅ-Ala, originating from Brevibac-
terium divaricatum [8,9].
Peptidoglycans activate macrophages via TLR2 receptor,
whereas MDP lacks TLR2-agonistic activity [10]. PGM and
MDP have similar immunostimulating activity and they are
reduced in comparison to the potent complete Freund’s adju-
vant which is used as golden standard for adjuvant activity [11].
However, strong toxicity of complete Freund’s adjuvant
disables its clinical application. MDP is too pyrogenic for clini-
cal application as well and suﬀers from rapid elimination.
Therefore, numerous MDP analogues and derivatives were syn-
thesized, in order to improve the properties of the parent mole-
cule [12-16]. Replacement of the N-acetylmuramyl moiety with
various acyl groups represents an important approach in the
design of new immunologically active MDP analogues [17].
MDP analogues lacking the N-acetylmuramyl group are called
desmuramyl peptides. Structure–activity studies of the MDP de-
rivatives and analogues suggest that the ʟ-Ala-ᴅ-isoGln pharma-
cophore is essential for the immunostimulatory properties but
the introduction of lipophilic substituent into MDP analogues
can increase its adjuvant activity [12,18]. Up to now, our
research was directed towards isomeric desmuramyl peptides
containing lipophilic unnatural amino acid, adamantylglycine
(AdGly), bound to the N-terminus of ʟ-Ala-ᴅ-isoGln dipeptide
part as well as their mannosylated derivatives. Different isomers
of mannosylated adamantyl tripeptides, regarding the chiral
centers introduced at adamantylglycine and spacer which
connect the sugar part to the adamantyltripeptide were synthe-
sized and biologically evaluated [19-21]. The best adjuvant ac-
tivity in experiments in vivo showed the ManAdTP derivative
(Figure 2) which has a ᴅ-configuration at the (adamant-1-
yl)glycine moiety and (R)-configuration at the hydroxyisobu-
tyryl linker. Its activity was higher than PGM that was used as
reference compound.
Figure 2: Immunostimulating mannosylated desmuramyl peptide
(ManAdTP).
The results indicate that introduction of mannose plays a signif-
icant role in stimulation of the immune response and the possi-
bility of effecting the immune response by the mannose recep-
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Figure 3: General structure of: a) glycolyl and b) (R)-hydroxyisobutyryl derivatives.
tor family, group I CLRs, present on immunocompetent cells
(such as macrophages and dendritic cells) [22,23]. It has been
shown that uptake of liposomes displaying mannose ligands at-
tached to the surface enhanced the uptake in human monocyte-
derived dendritic cells [24].
Here we describe a structure–activity relationship (SAR) study
on novel mannosylated desmuramyl peptide derivatives in
which two series of compounds were prepared: (i) derivatives
containing a glycolyl linker between mannose and dipeptide,
and (ii) derivatives containing a parent (R)-hydroxyisobutyryl
linker (Figure 3). In both series, positions of adamantane
binding (to the N- or C-terminus) were altered in comparison
with derivatives lacking the adamantane moiety. Immunostimu-
lating properties of synthesized derivatives were assessed in
vivo using ovalbumin as an antigen.
Results and Discussion
Design
Desmuramyl peptides enter into the cell by passive absorption
and this process depends on lipophilicity [25]. Numerous ana-
logues and derivatives which incorporated different lipophilic
groups have shown improved activity [14,18,21,26]. To enable
the systematic investigation of influence of lipophilic adaman-
tane on the immunostimulating activity, derivatives with altered
position of the adamantane moiety (at the N- or C-terminus of
the dipeptide), as well as derivatives lacking the adamantane
moiety, were prepared. Furthermore, herein we describe a
strategy for the preparation of two series of mannose MDP ana-
logues based on the ManAdTP hit compound. The attachment
of mannose to the desmuramyl dipeptide may contribute to the
recognition of the adjuvant compound by specific mannose re-
ceptors expressed at immune cells. Mannosylated drug delivery
systems enhance uptake and activation of dendritic cells and
increase T cell proliferation [24,27,28]. Mannosylation of the
adamantylated desmuramyl peptides amplified the adjuvant ac-
tivity in experiments in vivo [20,21]. Two series of manno-
conjugates were prepared: (i) derivatives with glycolyl linker
and (ii) the ones with (R)-hydroxyisobutyryl linker which is
present in the parent ManAdTP. The glycolic linker was intro-
duced due to the fact that N-glycolyl muramyl peptides induce
significantly higher activation of NOD2 than MDP [29,30].
Mycobacteria present in complete Freund’s adjuvant, and
related Actinomycetes, produce N-glycolyl MDP by the
hydroxylase action on MDP (N-acetylmuramic acid within the
peptidoglycan). The influence of structural modifications on
immunomodulating properties was estimated by the immunos-
timulatory effect on secondary humoral response to ovalbumin
(antigen) in BALB/c mice.
Chemistry
Peptide building blocks were prepared starting from the fully
protected desmuramyl peptide, Boc-ʟ-Ala-ᴅ-isoGlnOBn. For
the synthesis of derivatives lacking the adamantane moiety,
dipeptide 1 with benzyl protection on the C-terminus was ob-
tained after Boc-deprotection as previously reported (Scheme 1)
[31]. Peptide 1 was also used for the synthesis of adamantly-
containing desmuramyl tripeptide 3.
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Scheme 1: Synthesis of desmuramyl peptides modified at N-terminus. Reagents and conditions: a) TFA/DCM 1:2, rt, 1 h, quantitative; b) EDC·HCl,
HOBt·H2O, Et3N, DCM/dioxane 1:1, 0 °C → rt, 48 h, 82%; c) TFA/DCM 1:2, rt, 1 h followed by chromatographic separation of isomers, 43%.
Scheme 2: Synthesis of C-modified desmuramyl peptides. Reagents and conditions: a) H2, 10% Pd/C, MeOH, 38 psi, rt, 24 h, 96%; b) adamant-1-
ylamine hydrochloride, EDC·HCl, HOBt·H2O, Et3N, DCM/dioxane 1:1, 0 °C → rt, 48 h, 60%; c) TFA/DCM 1:2, rt, 1 h, quantitative.
Compound 1 was coupled with previously prepared racemic
Boc-protected (adamant-1-yl)glycine [32] 2 using the carbo-
diimide EDC/HOBt method [21]. The obtained mixture of
BocAdGly-ʟ-Ala-ᴅ-isoGlnOBn diastereoisomers was treated
with trifluoroacetic acid in order to remove the Boc protecting
group while the diastereoisomer 4 with ᴅ-ʟ-ᴅ amino acid se-
quence was separated from the isomer mixture using silica gel
column chromatography and CHCl3/MeOH 1:1 as eluent. The
spectral data of the isolated isomer 4 were compared to the
published ᴅ-AdGly-ʟ-Ala-ᴅ-isoGln prepared from tripeptide
tert-butyl ester [21]. Desmuramyl peptides 1 and 4 were further
used for condensation reactions with hydroxyisobutyryl and
glycolyl mannosides. The synthesis of desmuramyl peptide 7
with an adamantane moiety bound at C-terminus is presented in
Scheme 2.
After hydrogenolysis of the starting dipeptide, condensation of
free carboxyl group with adamant-1-ylamine hydrochloride was
performed. Boc deprotection of obtained compound 6 gave the
trifluoroacetic salt of peptide 7 which was used in the synthesis
of mannoconjugates. The mannose precursor containing the
glycolyl linker 11 was prepared in a three-step procedure shown
in Scheme 3.
The stereoselective α-anomeric deacetylation of peracetylated
mannose 8 was performed using the mild acidic catalyst, zinc
acetate hydrate [33]. The reaction progress was monitored by
thin-layer chromatography. Within the first 20 hours compound
9 was the only product and further progress resulted in gradual
removal of the remaining acetate groups. The SN2 substitution
of bromine from tert-butyl bromoacetate with 2,3,4,6-tetra-O-
acetyl-α-ᴅ-mannopyranose (9) in the presence of potassium
carbonate followed. Chemoselective removal of the tert-butyl
ester group from compound 10 resulted with O-mannoside 11
with a free carboxy group available for coupling of the peptide
moieties. The tert-butyl deprotection was accomplished using a
selective reagent, trifluoroacetic acid (TFA). Side products
derived from deacetylation of compound 10 have not been
detected. The synthesis of benzyl-protected α-mannoside con-
taining a (R)-hydroxyisobutyryl linker was previously de-
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Scheme 3: Synthesis of the mannose precursor. Reagents and conditions: a) Zn(OAc)2·H2O, abs. MeOH, rt, 20 h, 60%; b) BrCH2COOC(CH3)3,
K2CO3, dry DMF, rt, 2 h, 81%; c) TFA, dry DCM, rt, 1,5 h, 72%.
Scheme 4: Synthesis of mannosylated peptides with hydroxyisobutyryl linker. Reagents and conditions: a) EDC·HCl, HOBt·H2O, Et3N, DCM/dioxane
1:1, 0 °C → rt, 48 h, 52–90%; (b) H2, 10% Pd/C, 48 h, rt, 83–92%.
scribed [34]. Condensations of peptides 1, 4 and 7 with
carboxy-functionalized mannosides containing a (R)-hydroxy-
isobutyryl and glycolyl linker are shown in Scheme 4 and
Scheme 5, respectively.
For the amide bond formation between mannose and peptide
part, an optimized EDC/HOBt method was used in each case.
Synthesized compounds represent a small series of manno-
sylated desmuramyl peptides designed in a way that the intro-
duced structural differences could answer two key questions:
(i) Will the glycolyl linker in this class of compounds amplify
immunostimulatory activity similar to the N-glycolyl derivative
of MDP?, (ii) which relative position of the adamantane group
in the mannosylated desmuramyl peptides causes the greatest
increase of the adjuvant activity?
Testing of immunostimulating activity
The adjuvant activity was estimated by the immunostimulatory
effect on secondary humoral response to the well-established
model antigen ovalbumin (OVA) in BALB/c mice (Figure 4)
according to previously described in vivo studies [11,35]. Anti-
OVA IgG, anti-OVA IgG1 and anti-OVA IgG2a were deter-
mined in the mice sera after supplementing the mice with the
second booster. The comparison of induced anti-OVA IgG
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Scheme 5: Synthesis of mannosylated peptides with glycolyl linker. Reagents and conditions: a) EDC·HCl, HOBt·H2O, Et3N, DCM/DMF 1:1,
0 °C → rt, 72 h, 26–67%; b) NaOMe/MeOH, rt, 1 h, 59–89%.
levels was carried out quantitatively and the subclasses of IgG,
IgG1 and IgG2a, as indicators of Th1 or Th2 type of immune
response, were also determined. The adjuvant activity of syn-
thesized compounds was evaluated in comparison to the
mannosylated adamantyl tripeptide ManAdTP and PGM. PGM
was used as reference adjuvant in previously published studies
since PGM and MDP have similar immunological properties:
both stimulate the Th2-biased immune response specific for the
OVA antigen [11,35].
In general, when compared to the group treated with no adju-
vant (OVA alone), enhancement in total anti-OVA IgG anti-
body production was observed in all groups except in group that
received 16 (Figure 4). High levels of IgG antibody present
even in the OVA treated group, led to a relatively weak stimula-
tion of the total antibody production in the PGM-injected group.
ManAdTP elicited a better immune response than OVA alone
and the PGM-injected group. These results are in very good
agreement with previous research where stimulation of anti-
OVA IgG antibody production by ManAdTP and parent non-
Figure 4: The effect of mannosyl desmuramyl peptides on production
of anti-OVA IgG in BALB/c mice immunized with OVA as an antigen.
Bar graphs represent average values from individual mice from each
group (n = 5). *p < 0.05, **p < 0.01 and ***p < 0.001 denote the statis-
tical significance in comparison to the control group or groups
connected with a line.
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Figure 5: The effect of mannosylated desmuramyl peptides on production of anti-OVA IgG subtypes, anti-OVA IgG1 (a) and anti-OVA IgG2a (b), re-
spectively, in BALB/c mice immunized with OVA as an antigen. Bar graphs represent average values from individual mice from each group (n = 5).
*p < 0.05 and ***p < 0.001 denote statistical significance in comparison to the control group.
mannosylated AdTP were investigated in the NIH/OlaHsd
mouse model in comparison to PGM [36]. In BALB/c mice
used in this study, enhancement in the total anti-OVA IgG anti-
body production by ManAdTP is statistically significant
(p < 0.01). A statistically significant boost in antibody
responses to the OVA antigen was observed in all groups
immunized with compounds containing a glycolyl linker
(p < 0.05 and and p < 0.001) in comparison to the control
group. Immunization with compound 21 which has an
adamantly tripeptide moiety attached to mannose through the
glycolyl linker led to the highest and statistically most signifi-
cant increase in the specific IgG response (p < 0.001). Addition-
ally, amplification in the total IgG antibody production was ob-
served in all groups immunized with mannosylated desmu-
ramyl peptides containing a glycolyl linker 20–22 relatively to
analogues 15, ManAdTP and 16. The results directly indicate
that the introduction of the glycolyl linker plays a significant
role in stimulation of the immune response in this class of adju-
vants. Similarly, N-glycolyl muramyl peptides obtained by the
oxidation of the N-acetyl group of MDP induce significantly a
higher activation of NOD2 than MDP [29,30]. Glycopeptide 21
was identified as the most potent adjuvant in this experiment
and in this class of adjuvants, so far. Introduction of the
lipophilic moiety positively influences the adjuvant properties
of MDP derivatives and analogues [12]. In both, hydroxyisobu-
tyryl and glycolyl derivatives, introduction of the bulky and
lipophilic adamantane showed to be suitable for the immunos-
timulatory activity. The adjuvant activity changes in respect to
the position of adamant-1-yl moiety in the peptide part. Anti-
OVA IgG antibody stimulation was higher in the groups immu-
nized with ManAdTP and 21 in respect to groups treated with
16 and 22, respectively. This leads to the conclusion that the
most suitable position of adamantane in this class of com-
pounds is at the peptide N-terminus. Adamantane can act as
membrane anchor for mannose structures and thus be exposed
on liposome surfaces and as such used in targeted drug delivery
[37]. It can be also incorporated into a β-cyclodextrine cavity, a
powerful supramolecular nanoparticle carrier for targeted drug
delivery [38]. Previous research suggested a design of manno-
sylated desmuramyl peptides with adamantane at the
C-terminus in order to facilitate the incorporation into the
hydrophobic layer of the cavity because of the minor steric
hindrance of the mannose and peptide part during the inclusion
process of the adamantane [37,39].
It is well known that vaccine adjuvants can enhance or modu-
late the Th1/Th2-bias of an induced immune response. Inter-
feron-γ (as a Th1 cytokine) and IL-4 (as a Th2 cytokine) in-
duce isotype switching to IgG2a and IgG1, respectively. There-
fore, isotype profile of antigen specific anti-OVA IgG anti-
bodies, IgG1 and IgG2a, is usually measured as a marker of the
Th1 and Th2 type immune response bias [40,41]. In this study,
the type of generated immune response was indirectly esti-
mated by quantification of OVA-specific IgG1 (for activation
of Th2 type) and IgG2a (for activation of Th1 type) and calcula-
tion of the respective IgG1/IgG2a ratio. When the amount of
anti-OVA IgG1 antibodies was measured (Figure 5a), it was ob-
served that in all groups high levels of IgG1 antibody was
present and the highest response, which was also statistically
significant (p < 0.001), was given by compound 21. A slight
suppression was noticed only in the production of anti-OVA
IgG1 antibodies when compound 16 was administered.
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A statistically significant enhancement in anti-OVA IgG2a pro-
duction (Figure 5b) was observed in groups immunized with
mannosylated adamantyl-tripeptides, ManAdTP and 21. The
type of immune response was indirectly determined by quantifi-
cation of IgG1 (for activation of Th2-type) and IgG2a (for acti-
vation of Th1-type) antibody for each serum (obtained after the
second booster) and calculation of the IgG1/IgG2a ratio
(Figure 6).
Figure 6: The ratio of anti-OVA IgG1 and anti-OVA IgG2a (IgG1/
IgG2a) in BALB/c mice. For each mouse serum IgG1/IgG2a was calcu-
lated and the result for each experimental group (n = 5) is presented
as average ± standard deviation (SD). ***p < 0.001 denote statistical
significance in comparison to the control group.
From the IgG1/IgG2a ratio it is evident that all groups treated
with tested adjuvants have higher values than the group treated
with OVA alone, indicating the slight shift toward more pro-
nounced Th2 type of immune response. Compound 22 signifi-
cantly switches immune response toward pronounced Th2 type,
due to the predominant appearance of IgG1 antibodies. MDP
and PGM dominantly induce the IgG1 antibody production and
stimulate the Th2-polarized immune response as well [11,42]. It
is well known that muropeptides act as NOD2 agonists and in-
duce a predominant Th2-biased response [43]. NOD2 agonists
have the ability to act synergistically and augment the adjuvant
activity of TLR ligands [10,44-46]. Furthermore, a combina-
tion of PRR ligands, such as NLR/TLR, induce Th1-polarized
response. This NLR/TLR crosstalk is essential for modulation
of innate and adaptive immune responses and leads to develop-
ment of new approaches for the design of novel vaccines. Ap-
plication of multi-PRR activation approaches can increase the
immunity significantly [47]. Another example of dual adjuvant
system is represented by the activation of dendritic cells via
combined macrophage-inducible CLR and TLR ligands [48].
Mannose receptors are one group in the CLRs family which
exist as soluble and transmembrane receptors [4]. Like TLRs
they initiate innate immune responses and activate acquired
immunity. Mannose structures on the other hand, are one of the
glycan structures that build up tumor antigens and regulate the
immune reaction by specific binding to CLRs. Therefore, com-
pounds with expressed CRL agonist or antagonist properties
could also be considered as potential agents for cancer
immunotherapy [49,50]. Mannosylated liposomes with incorpo-
rated MDP have proved to be effective carriers for target inhibi-
tion of liver metastasis [51]. Therefore, the presented manno-
sylated desmuramyl peptides with incorporated adamantane
will be further explored in order to get a better insight into
possible PRR crosstalk. Namely, inclusion of adamantane into
carriers such as liposomes can additionally affect the Th1/Th2
switch of the immune response [52]. The presented results
demonstrate the great immunostimulating potential of glycolyl-
modified desmuramyl peptides. Peptidoglycan fragments with
mycobacterial structural features, such as synthesized com-
pounds 20–22, could efficiently link innate and adaptive immu-
nity, similarly as N-glycolyl MDP enhances the innate immune
response and T cell-mediated immunity [53]. NOD2-activation
and interaction with CLR should be further explored, as well as
a potential for synergistic multi-PRR activation.
Conclusion
A series of novel mannosylated desmuramyl peptides were pre-
pared and characterized. In their structures, all glycopeptides
comprised of mannose and the key pharmacophore – desmu-
ramyl peptide. These moieties are connected through a glycolyl
or hydroxyisobutyryl linker and additionally modified on N/C
terminus with an adamantane subunit. The immunostimulating
activities of tested compounds were compared to hit com-
pounds ManAdTP and PGM. In in vivo experiments, all
mannopeptides with a glycolyl linker exhibited higher adjuvant
activity than analogues with a hydroxyisobutyryl linker indicat-
ing that the introduction of the glycolyl moiety plays a signifi-
cant role in the stimulation of the immune response. In particu-
lar, compound 21 was identified, so far, as the most potent adju-
vant in this class of mannosylated desmuramyl peptides. It
should be also noted that the compound 21 is stable, non-pyro-
genic and water-soluble what makes it potentially applicable as
an adjuvant for vaccines.
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